We are advising GSK on the transaction

Davis Polk is advising GSK plc on its acquisition of Nuvalent, Inc. for approximately $10.6 billion. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.

GSK is a global biopharmaceutical company with a purpose to unite science, technology and talent to get ahead of disease together.

Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.

The Davis Polk corporate team includes partners William J. Chudd and Daniel Brass and counsel Saagar Kaul. Partner Jennifer S. Conway and associate Josh (Joshua) Ehrhart are providing executive compensation advice. Partner David R. Bauer and associate Francesca Masella are providing intellectual property advice. Partner Howard Shelanski and counsel Suzanne Munck af Rosenschold are providing antitrust and competition advice. Partner William A. Curran is providing tax advice. Members of the Davis Polk team are based in the New York and Washington DC offices.

Copy link to share post